Articles

How pharma should harness mobile technology

27th November 2014

How pharma should harness mobile technologyDan Brilot

A huge proportion of the adult population now carries a smartphone, so pharma and healthcare providers need to look to this 'doctor in your pocket' potential to augment the face-to-face... Read more

Broadening the RWD conversation

26th November 2014

Broadening the RWD conversationJacky Law

There can be few pharma CEOs who are not acutely aware of the data revolution exploding around them and the need to enhance their data analytics capabilities. But technical expertise... Read more

Making sense of pharma’s financial relationships with physicians

25th November 2014

Making sense of pharma’s financial relationships with physiciansAshish Kalgaonkar

Details of payments made to doctors and hospitals in the US are now available to view online, as necessitated by the 'Sunshine Act' health care reforms. So what does this... Read more

Access strategy for success in emerging markets

24th November 2014

Access strategy for success in emerging marketsWilliam Kammerer and Anastasia Thatcher

Over the past two decades nations of lower-middle income and upper-middle-class consumers have developed. This 'Emerging Middle Class', with an average per capita income of between $1,000 and $12,000, now... Read more

News

Positive early results for GSK/NIAID Ebola vaccine

27th November 2014

Positive early results for GSK/NIAID Ebola vaccineLinda Banks

A phase I trial on an experimental vaccine to prevent Ebola virus disease show it was well-tolerated and produced immune system responses in all 20 healthy adults who received it.Co-developed... Read more

UK government launches mental health taskforce

26th November 2014

UK government launches mental health taskforceLinda Banks

Following the October announcement that £120 million is to be invested in mental health services, a new mental health taskforce is to be established and chaired by Deputy Prime Minister... Read more

BioMarin offers $840m for muscular dystrophy firm Prosensa

25th November 2014

BioMarin offers $840m for muscular dystrophy firm ProsensaStaff reporter

Rare disease specialist BioMarin has agreed to acquire Prosensa and its Duchenne muscular dystrophy (DMD) candidate drisapersen in a deal valued at up to around $840 million. The US company... Read more

IMS Health partners with pharmaphorum on cancer educational programme

25th November 2014

IMS Health partners with pharmaphorum on cancer educational programmeLinda Banks

With the approach of the General Election, healthcare strategies, budgets, the NHS and the future of the Cancer Drugs Fund are all in the headlines and pharmaphorum has its finger... Read more

Audio & Video

Dec 8th: Live webinar - The Price is Rig…

Slide-300x200b

 

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the... View more

Now on demand - real world insight into …

The Diabetes Debate

 

Now available on demand (free to access) - originally broadcast on October 29th 2014.


Non-adherence to self-management regimens in diabetes is globally... View more

On-demand webinar: Is pharma brand marke…

Kantar Health webinar


While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to... View more

View the conversation - Tweetchat: Manag…

Atlantis Healthcare diabetes Tweetchat


Working in partnership, Atlantis Healthcare and pharmaphorum conducted a Tweetchat focussed on the real world challenges patients face in managing... View more

White Papers

"The future ain’t what it used to b…

"The future ain’t what it used to be"Paul Stuart-Kregor

Preparation is key to creating and maintaining a strong drugs pipeline. However, the statistics demonstrate that successful product commercialisation strategies are not always implemented. Products are developed for which there... View info

Healthcare Innovation: the big ideas sha…

Healthcare Innovation: the big ideas shaping the future of pharmaDavid Rowley

The transformation taking place in healthcare is challenging for everyone and adaptability is key for the pharma industry's continued success.

Long production cycles, concentration on specialist drugs with high... View info

Giving a voice to those with heart valve…

Giving a voice to those with heart valve disease

Although over a million people in the UK today have heart valve disease, it remains an overlooked condition. Despite the priority being given to cardiovascular disease in the UK, it... View info

Pricing & Market Access Outlook 2014

Pricing & Market Access Outlook 2014

Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need,... View info

Further News & Articles

AstraZeneca COPD drug combination approved in EU

AstraZeneca's (AZ) Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketin... Read more

News

AbbVie's oral hepatitis C regimen backed for EU approval

AbbVie has closed in on the first approval of its four-drug hepatitis C virus regimen, after the EU's Committee ... Read more

News

RB spin-out Indivior says addiction pipeline will deliver

Earlier this week, Reckitt Benckiser (RB) made good on its promise to spin-out its pharmaceutical business in... Read more

News

Novartis novel psoriasis treatment gains positive opinion in Europe

Novartis' Cosentyx (secukinumab) is the first IL-17A inhibitor to receive a positive opinion from the Europea... Read more

News

UK aims to shave years off drug development

The UK government has announced an 'end to end' review of how drugs are developed, approved and accessed by pati... Read more

News

The ills inflicted by poor strategy

If brand managers adopt a policy of 'doing no harm', as doctors do, then strategies will be taken seriously and the ... Read more

Articles